Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy

Journal of Clinical Rheumatology

Volumn 16, Issue 2, 2010, Pages 76-78

  Breglia, Michael D ^a   Carter, John D ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Bisphosphonate; Fracture; Insufficiency fracture; Osteoporosis; Stress fracture

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; CYCLOPHOSPHAMIDE; ESTRADIOL; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EMERGENCY WARD; FATIGUE; FEMALE; FEMUR NECK; HUMAN; KNEE RADIOGRAPHY; LABORATORY TEST; LOW DRUG DOSE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TIBIA FRACTURE; VAGINA ATROPHY;

ADRENAL CORTEX HORMONES; ALENDRONATE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIPHOSPHONATES; FEMALE; FRACTURES, STRESS; HUMANS; MIDDLE AGED; TIBIAL FRACTURES; TIME FACTORS;

EID: 77949454726     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181cf3e3d     Document Type: Article

References (14)

1. Mashiba T, Turner CH, Hirano T, et al.. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531.
2. Mashiba T, Hirano T, Turner CH, et al.. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620.
3. Odvina CV, Zerwekh J, Rao S, et al.. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
4. Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab. 2001;86:1835.
5. Tonino RP, Meunier PJ, Emkey R, et al.. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85:3109-3115.
6. Imai K, Yamamoto S, Anamizu Y, et al.. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab. 2007;25:333-336.
7. Goh SK, Yang KY, Koh JS, et al.. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349-353.
8. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrin Metab. 2008;93:2948-2952.
9. Scheider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006;61:31-33.
10. Odvina CV, Levy S, Rao S, et al.. Unusual mid shaft fractures during long term bisphosphonate therapy. Clin Endocrinol. In press.
11. Bone HG, Greenspan SL, McKeever C, et al.. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85:720-726.
12. Degueker J, Maenaut K, Verwilghen J, et al.. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol. 1995;12:S21-S26.
13. Niva MH, Kiuru MJ, Haataja R, et al.. Bone stress injuries causing exerciseinduced knee pain. Am J Sports Med. 2006;34:78.
14. Kwek EB, Goh SK, Koh JS, et al.. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224-231.